ATE544344T1 - Therapeutische pyrazolochinolinderivate - Google Patents

Therapeutische pyrazolochinolinderivate

Info

Publication number
ATE544344T1
ATE544344T1 AT08770402T AT08770402T ATE544344T1 AT E544344 T1 ATE544344 T1 AT E544344T1 AT 08770402 T AT08770402 T AT 08770402T AT 08770402 T AT08770402 T AT 08770402T AT E544344 T1 ATE544344 T1 AT E544344T1
Authority
AT
Austria
Prior art keywords
formula
gabaa
pyrazolochinoline
therapeutic
derivatives
Prior art date
Application number
AT08770402T
Other languages
German (de)
English (en)
Inventor
Alan Kaplan
Varsha Gupta
Jan Wasley
Original Assignee
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc filed Critical Helicon Therapeutics Inc
Application granted granted Critical
Publication of ATE544344T1 publication Critical patent/ATE544344T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT08770402T 2007-06-08 2008-06-06 Therapeutische pyrazolochinolinderivate ATE544344T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94300507P 2007-06-08 2007-06-08
PCT/US2008/066201 WO2008154438A1 (en) 2007-06-08 2008-06-06 Therapeutic pyrazoloquinoline derivatives

Publications (1)

Publication Number Publication Date
ATE544344T1 true ATE544344T1 (de) 2012-02-15

Family

ID=40096440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08770402T ATE544344T1 (de) 2007-06-08 2008-06-06 Therapeutische pyrazolochinolinderivate

Country Status (13)

Country Link
US (2) US7872002B2 (cg-RX-API-DMAC7.html)
EP (1) EP2166852B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010529143A (cg-RX-API-DMAC7.html)
KR (1) KR20100039331A (cg-RX-API-DMAC7.html)
CN (1) CN101742908A (cg-RX-API-DMAC7.html)
AT (1) ATE544344T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008261884A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0812366A2 (cg-RX-API-DMAC7.html)
CA (1) CA2688395A1 (cg-RX-API-DMAC7.html)
ES (1) ES2386168T3 (cg-RX-API-DMAC7.html)
IL (1) IL202270A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009013202A (cg-RX-API-DMAC7.html)
WO (1) WO2008154438A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2688405A1 (en) * 2007-06-08 2008-12-18 Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline urea derivatives
CN101754681A (zh) * 2007-06-08 2010-06-23 海利空医疗公司 治疗用吡唑并萘啶衍生物
EP2166852B1 (en) * 2007-06-08 2012-02-08 Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline derivatives
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
JP2018537450A (ja) * 2015-11-16 2018-12-20 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ Ｄｎａメチルトランスフェラーゼ阻害剤としての新規化合物
CN105294648B (zh) * 2015-11-30 2017-11-28 山东罗欣药业集团股份有限公司 一种西他沙星的制备方法
WO2022037631A1 (zh) * 2020-08-21 2022-02-24 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3204126A1 (de) * 1982-02-06 1983-08-11 Bayer Ag, 5090 Leverkusen Pyrazoloxazine, -thiazine, -chinoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4814450A (en) 1984-07-09 1989-03-21 Ciba-Geigy Corporation Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives
JPS61112075A (ja) 1984-11-05 1986-05-30 Shionogi & Co Ltd チエニルピラゾロキノリン誘導体
EP0214092A1 (en) 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US5334595A (en) 1992-10-23 1994-08-02 Sterling Winthrop Inc. Pyrazoloquinolones as anticancer agents
GB9716347D0 (en) * 1997-08-01 1997-10-08 Merck Sharp & Dohme Therapeutic compounds
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
GB0108475D0 (en) * 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
JP3896309B2 (ja) 2001-07-09 2007-03-22 ファイザー株式会社 プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体
US7674906B2 (en) 2002-12-16 2010-03-09 Active Biotech Ab Tetracyclic immunomodulatory compounds
US20050245563A1 (en) 2003-05-29 2005-11-03 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CA2621560A1 (en) 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
JP2008047893A (ja) * 2006-08-11 2008-02-28 Samsung Electronics Co Ltd 薄膜トランジスタ表示板及びその製造方法
EP2166852B1 (en) * 2007-06-08 2012-02-08 Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline derivatives

Also Published As

Publication number Publication date
KR20100039331A (ko) 2010-04-15
MX2009013202A (es) 2010-04-09
EP2166852A1 (en) 2010-03-31
US8598159B2 (en) 2013-12-03
US7872002B2 (en) 2011-01-18
AU2008261884A1 (en) 2008-12-18
IL202270A0 (en) 2010-06-16
US20110065693A1 (en) 2011-03-17
JP2010529143A (ja) 2010-08-26
HK1142775A1 (en) 2010-12-17
WO2008154438A1 (en) 2008-12-18
BRPI0812366A2 (pt) 2016-08-02
CA2688395A1 (en) 2008-12-18
ES2386168T3 (es) 2012-08-10
EP2166852B1 (en) 2012-02-08
CN101742908A (zh) 2010-06-16
EP2166852A4 (en) 2010-07-07
US20080306049A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
EA201100447A1 (ru) Органические соединения
EA200802213A1 (ru) Способы лечения заболеваний крови
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
EA201000007A1 (ru) Производные индазоламида
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
ATE544344T1 (de) Therapeutische pyrazolochinolinderivate
EA200801897A1 (ru) Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений
NO20070855L (no) Arylidener for behandling av estrogenrelaterte reseptor-alfamedierte sykdommer.
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA200802329A1 (ru) Производные триазола ii
ATE530524T1 (de) Substituierte sulfonamid-derivate
UA94639C2 (ru) Трициклические соединения и их применение как модуляторов глюкокортикоидного рецептора
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
EA201100623A1 (ru) Сульфоксиминзамещенные анилинопиримидиновые производные в качестве cdk ингибиторов, их получение и применение в качестве лекарственных средств
EA201000362A1 (ru) Производные 1,3-дигидроизоиндола
MX2009013205A (es) Derivados de pirazoloquinolina urea terapeuticos.
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
EA201100872A1 (ru) Производные хиназолинамида
DE602007006328D1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
MX2009013197A (es) Derivados terapeuticos de pirazolonaftiridina.
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique